|
Real-time Estimate
Cboe BZX
11:44:42 2026-09-25 EDT
|
5-day change | 1st Jan Change | ||
| 34.94 USD | +0.33% |
|
+0.52% | +13.38% |
| 09-24 | AbbVie Says Health Canada Issues Notice of Compliance for EPKINLY in Follicular Lymphoma | MT |
| 09-24 | Hansa Biopharma brings in two new board members | FW |
Company Valuation: Genmab A/S
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 172,063 | 192,229 | 140,770 | 94,810 | 124,862 | 135,522 | - | - |
| Change | - | 11.72% | -26.77% | -32.65% | 31.7% | 8.54% | - | - |
| Enterprise Value (EV) 1 | 152,725 | 169,905 | 112,635 | 73,709 | 114,029 | 154,695 | 146,558 | 133,740 |
| Change | - | 11.25% | -33.71% | -34.56% | 54.7% | 35.66% | -5.26% | -8.75% |
| P/E | 57.8x | 35.2x | 32.6x | 12.3x | 20.9x | 28.3x | 20.3x | 13.5x |
| PBR | 7.82x | 7.07x | 4.5x | 2.68x | 3.47x | 3.38x | 2.88x | 2.39x |
| PEG | - | 0.4x | -1.5x | 0.1x | -1x | -1.6x | 0.5x | 0.3x |
| Capitalization / Revenue | 20.3x | 13.2x | 8.54x | 4.4x | 5.31x | 4.67x | 4.03x | 3.32x |
| EV / Revenue | 18x | 11.6x | 6.84x | 3.42x | 4.85x | 5.34x | 4.36x | 3.28x |
| EV / EBITDA | 46.8x | 25.3x | 20.1x | 10.4x | 15.9x | 17.7x | 11.7x | 7.79x |
| EV / EBIT | 50.6x | 26.7x | 21.2x | 10.5x | 17x | 19.9x | 14.6x | 9.39x |
| EV / FCF | 77.3x | 47.3x | 16.1x | 9.72x | 15.7x | 25.9x | 19.1x | 11.2x |
| FCF Yield | 1.29% | 2.12% | 6.23% | 10.3% | 6.36% | 3.87% | 5.23% | 8.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 45.54 | 83.65 | 66.02 | 121.4 | 97.08 | 80.01 | 111.5 | 167.5 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 8,482 | 14,595 | 16,474 | 21,526 | 23,497 | 28,994 | 33,646 | 40,818 |
| EBITDA 1 | 3,266 | 6,719 | 5,616 | 7,116 | 7,175 | 8,716 | 12,478 | 17,161 |
| EBIT 1 | 3,018 | 6,357 | 5,321 | 7,003 | 6,727 | 7,783 | 10,006 | 14,247 |
| Net income 1 | 3,008 | 5,522 | 4,352 | 7,844 | 6,083 | 4,973 | 7,094 | 10,674 |
| Net Debt 1 | -19,338 | -22,324 | -28,135 | -21,101 | -10,833 | 19,173 | 11,035 | -1,782 |
| Reference price 2 | 2,630.00 | 2,941.00 | 2,155.00 | 1,492.50 | 2,027.00 | 2,268.00 | 2,268.00 | 2,268.00 |
| Nbr of stocks (in thousands) | 65,423 | 65,362 | 65,322 | 63,524 | 61,599 | 59,754 | - | - |
| Announcement Date | 2/16/22 | 2/22/23 | 2/14/24 | 2/12/25 | 2/17/26 | - | - | - |
1DKK in Million2DKK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.09x | 7.5x | 15.07x | 1.41% | 71.94B | |
| 30.84x | 8.88x | 27.67x | 0.04% | 59.35B | |
| 31.46x | 6.7x | 17.4x | -.--% | 27.16B | |
| -74.58x | 14.32x | -78x | -.--% | 26.54B | |
| -15.32x | 5.85x | -7.35x | -.--% | 24.93B | |
| 28.35x | 5.34x | 17.75x | -.--% | 20.61B | |
| 43.56x | 15.96x | 32.38x | 0.35% | 15.03B | |
| 1013.62x | 35.48x | 612.89x | -.--% | 14.2B | |
| 17.9x | 5.33x | 12.45x | -.--% | 14.36B | |
| Average | 121.88x | 11.71x | 72.25x | 0.2% | 30.46B | |
| Weighted average by Cap. | 64.68x | 9.87x | 38.96x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GMAB Stock
- GMAB Stock
- Valuation Genmab A/S
Select your edition
All financial news and data tailored to specific country editions
